NephroGenex (NASDAQ: NRX) and Allergan plc (NYSE:AGN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.
This table compares NephroGenex and Allergan plc’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current recommendations for NephroGenex and Allergan plc, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
NephroGenex presently has a consensus target price of $17.50, suggesting a potential upside of 12,391.08%. Allergan plc has a consensus target price of $277.76, suggesting a potential upside of 24.01%. Given NephroGenex’s stronger consensus rating and higher possible upside, analysts plainly believe NephroGenex is more favorable than Allergan plc.
Valuation & Earnings
This table compares NephroGenex and Allergan plc’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Allergan plc||$15.07 billion||4.97||$6.15 billion||$28.15||7.96|
Allergan plc has higher revenue and earnings than NephroGenex.
Allergan plc pays an annual dividend of $2.80 per share and has a dividend yield of 1.3%. NephroGenex does not pay a dividend. Allergan plc pays out 9.9% of its earnings in the form of a dividend.
Insider and Institutional Ownership
83.6% of Allergan plc shares are held by institutional investors. 0.4% of Allergan plc shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Allergan plc beats NephroGenex on 8 of the 11 factors compared between the two stocks.
NephroGenex Company Profile
NephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.
Allergan plc Company Profile
Allergan, Inc. is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates in two segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and prescription and OTC skin care products, and urologics products. The medical devices segment produces medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.
What are top analysts saying about NephroGenex Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NephroGenex Inc and related companies.